Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Illumina's RapidTrack Whole Genome Sequencing Service; BGI's Exome Sale


Illumina has launched its RapidTrack Whole Genome Sequencing Service, which uses the HiSeq 2500 sequencing instrument and the company's new iSAAC genome alignment software to sequence and align a whole human genome in five days. The company currently guarantees a turnaround time of less than 14 days to allow for queue time. The service costs $9,500 per individual sample or $7,600 per genome for 50 or more samples.

BGI is now offering a sale on its whole human exome sequencing services through Aug. 31 for US and European customers. Exome sequencing at 100-fold coverage costs $1,799 per sample and at 200-fold coverage costs $2,599 per sample. Both packages include exome capture with the Agilent SureSelect 51M capture kit; sequencing on the Illumina HiSeq 2000; and 10 gigabases or 20 gigabases of data for the 100x and 200x packages, respectively. The services are available through BGI's Hong Kong facility or the [email protected] Joint Genome Center at the Children's Hospital of Philadelphia.

Additionally, the [email protected] center is also offering a fast turnaround service — four to six weeks for four to 400 samples — for an additional $50.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.